相关实验视频
Updated: Jan 16, 2026

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
10.3K
[赫斯佩雷丁通过调节AMPK/NLRP3通路来缓解多克索鲁比辛诱导的心脏毒性]
Aili Yan1, Mengyao Luo2, Jinrui Chang1
1Department of Basic Medical Sciences, Xi'an Medical University, Xi'an 710021, China.
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
|September 29, 2025
概括
赫斯佩雷丁 (Hes) 通过减少炎症来保护免受多克索鲁比 (DOX) 诱导的心脏损伤. 这种效应通过调节AMPK/NLRP3通路来调节,为心脏毒性提供了潜在的治疗策略.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 多克索鲁比 (DOX) 是一种具有显著心脏毒性的强效化疗剂.
- 炎症在DOX引起的心脏损伤的发展中起着至关重要的作用.
- AMPK/NLRP3炎症酶途径与炎症过程有关.
研究的目的:
- 调查素 (Hes) 是否可以缓解多克索鲁比 (DOX) 诱导的心脏毒性.
- 为了确定Hes是否通过减少炎症来发挥其保护作用.
- 阐明AMPK/NLRP3通路在Hes介导心脏保护中的作用.
主要方法:
- 利用暴露于DOX的C57/bl6小鼠和H9c2细胞来模拟心脏毒性.
- 用 hesperetin (Hes) 和化合物C (CC,一种AMPK抑制剂) 来评估保护作用.
- 评估心脏功能,心肌病理,细胞活力,细胞亡和炎症标志物 (细胞因子,炎症组分) 通过生物化学测试,RT-PCR和西式涂抹.
主要成果:
- DOX诱导显著的心脏毒性,证据是心脏功能下降,心肌损伤,LDH活性增加和亡升高.
- 在DOX治疗上调节了促炎细胞因子 (TNF-α,IL-6,IL-1β) 和炎症蛋白 (NLRP3,ASC,caspase-1),同时降低了p-AMPK和p-mTOR的调节.
- 赫斯佩雷丁 (Hes) 治疗减轻了DOX诱导的心脏毒性和炎症,这种效应被C化合物逆转,表明AMPK通路参与.
结论:
- 赫斯佩雷丁 (Hes) 有效地减轻了多克索鲁比 (DOX) 引起的心脏毒性.
- 它通过调节AMPK/NLRP3通路来抑制炎症来实现心脏保护.
- 使用Hes准AMPK/NLRP3通路为治疗化疗引起的心脏损伤提供了一个有前途的治疗途径.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Cardiomyopathy III: Hypertrophic Cardiomyopathy
411
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
411
Cardiomyopathy V: Interprofessional Care
338
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338
Heart Failure Drugs: Diuretics
807
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
807

